Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Icon ( (ICLR) ) has provided an update.
On September 2, 2025, ICON plc announced its participation in upcoming investor conferences, with COO Barry Balfe presenting at the Baird 2025 Global Healthcare Conference and CEO Dr. Steve Cutler participating at the Deutsche Bank 2025 Healthcare Summit. These engagements are part of ICON’s efforts to maintain its strong industry positioning and communicate its strategic direction to stakeholders, reflecting its commitment to transparency and engagement with the investment community.
The most recent analyst rating on (ICLR) stock is a Buy with a $198.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score reflects its strong financial health and positive technical indicators, despite some challenges in revenue growth and elevated cancellations. The company’s strategic focus on growth areas and efficient operations support a favorable outlook.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a world-leading clinical research organization headquartered in Dublin, Ireland. The company specializes in providing outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. ICON is known for advancing clinical research from molecule to medicine, driving emerging therapies forward, and improving patient lives. As of June 30, 2025, ICON employed approximately 39,900 employees across 95 locations in 55 countries.
Average Trading Volume: 1,300,701
Technical Sentiment Signal: Sell
Current Market Cap: $13.84B
Find detailed analytics on ICLR stock on TipRanks’ Stock Analysis page.